GSA Capital Partners LLP Acquires 23,237 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)

GSA Capital Partners LLP lifted its stake in Cytek Biosciences, Inc. (NASDAQ:CTKB) by 158.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 37,884 shares of the company’s stock after purchasing an additional 23,237 shares during the period. GSA Capital Partners LLP’s holdings in Cytek Biosciences were worth $210,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in CTKB. Vanguard Group Inc. lifted its position in Cytek Biosciences by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 12,012,805 shares of the company’s stock valued at $80,606,000 after purchasing an additional 122,105 shares during the period. Dimensional Fund Advisors LP increased its holdings in Cytek Biosciences by 6.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,465,122 shares of the company’s stock valued at $8,175,000 after purchasing an additional 89,615 shares during the last quarter. Millennium Management LLC grew its holdings in Cytek Biosciences by 3,452.2% during the second quarter. Millennium Management LLC now owns 946,490 shares of the company’s stock valued at $5,281,000 after purchasing an additional 919,845 shares during the period. Bank of New York Mellon Corp raised its holdings in Cytek Biosciences by 3.8% in the second quarter. Bank of New York Mellon Corp now owns 804,261 shares of the company’s stock worth $4,488,000 after purchasing an additional 29,579 shares during the period. Finally, Principal Financial Group Inc. increased its position in shares of Cytek Biosciences by 4.8% in the 3rd quarter. Principal Financial Group Inc. now owns 503,172 shares of the company’s stock valued at $2,788,000 after buying an additional 23,028 shares in the last quarter. Institutional investors and hedge funds own 69.46% of the company’s stock.

Cytek Biosciences Price Performance

Shares of Cytek Biosciences stock opened at $6.55 on Monday. The firm has a market cap of $843.71 million, a price-to-earnings ratio of -81.88 and a beta of 1.32. The stock’s 50-day moving average is $5.52 and its 200-day moving average is $5.70. Cytek Biosciences, Inc. has a one year low of $4.66 and a one year high of $9.87.

Cytek Biosciences (NASDAQ:CTKB) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%. The firm had revenue of $51.50 million during the quarter, compared to the consensus estimate of $50.63 million. During the same quarter in the prior year, the firm posted ($0.03) EPS. On average, equities analysts expect that Cytek Biosciences, Inc. will post -0.06 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler raised their price target on Cytek Biosciences from $8.00 to $8.50 and gave the stock an “overweight” rating in a research report on Monday, November 11th.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.